http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220150814-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_113001f16b5885d43803e02dd4c831cd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9874f757fd39ada672edefbebbe411d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_638b2c8e587487939692f89c3176cb58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ca7c5443ab1734a8a501e03fd99d739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fb5155af7f89cc94a0d95cbbfa52d07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b172594d7beb17a5cf022290a5ef72f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae895b66a61064083a3e82032b23f0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9174744e71b31d684b9874fd278b1278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2834f6f51748a38faf6e4a7c4958c944 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f61230d7d9bd95c897d0e45bbee048 |
| publicationDate | 2022-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20220150814-A |
| titleOfInvention | Transformed professional antigen presenting cells specifically binding to antigen containing chimeric antigen receptor(CAR) and uses thereof |
| abstract | The present invention is a transformed antigen-specific professional antigen-expressing cell containing a chimeric antigen receptor (CAR), and specifically, the chimeric antigen receptor includes an antigen-binding domain that specifically binds to BAFF receptor, BCMA, and TACI It relates to a cell therapy or a pharmaceutical composition for the treatment of cancer and systemic lupus erythematosus, comprising the cells as an active ingredient. Transformed cells according to the present invention provide an enhanced chimeric signaling domain that induces the activity of professional antigen-presenting cells when they specifically bind to an antigen. As an example of this, a dimer in which a pair of extracellular domains of BAFF are linked to the human immunoglobulin G 1 heavy chain constant region, respectively, plays an important role in signal transduction of professional antigen-expressing cells. TLR-3, TLR-4 and IgE receptor gamma chain (Fcε receptor I gamma chain, FcεRIγ) or IgG receptor 2A alpha chain (Fcγ receptor 2A alpha chain, FcγR2Aα) or IgE receptor beta chain (Fcε receptor I beta chain, FcεRIβ) ) as a subunit of the immunoreceptor tyrosine-based activation motif (ITAM), and a novel synthetic intracellular signaling domain in which three ITAMs are connected by a linker. As a recombinant protein, , In the case of professional antigen-expressing cells transformed with vectors capable of overexpressing them, they have cytotoxicity specific to carcinoma and autoimmune diseases that express BAFF receptors, BCMA or TACI, thus providing immunity for the treatment of cancer and systemic lupus erythematosus. It can be usefully used as a cell therapy. |
| priorityDate | 2021-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 575.